

Monocyte Activation Test Market Size, Share & Trends Analysis Report By Product (MAT Kits, Reagents), By Source (PBMC Based, Cell Line Based), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

<https://marketpublishers.com/r/M03ABED99E91EN.html>

Date: January 2025

Pages: 180

Price: US\$ 5,950.00 (Single User License)

ID: M03ABED99E91EN

Abstracts

This report can be delivered to the clients within 3 Business Days

Monocyte Activation Test Market Growth & Trends

The global monocyte activation test market size is expected to reach USD 1.45 billion by 2030, registering a CAGR of 15.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by several key factors. Increasing regulatory pressure to replace animal testing with more ethical, human-relevant in vitro methods is a major driver. MAT's ability to provide accurate pyrogen detection using human immune cells makes it an attractive alternative to traditional endotoxin tests. The growing demand for biologics, vaccines, and complex pharmaceuticals further fuels MAT adoption, as safety is critical in these products. Additionally, advancements in biotechnology and the increasing emphasis on patient safety and quality control in drug development are contributing to the market's growth.

Technological innovations are significantly driving the growth of the Monocyte Activation Test (MAT) market. One of the key advancements is the development of more efficient and reproducible cell culture systems, particularly the use of immortalized human cell lines like THP-1 and U937 cells. These cell lines enhance the accuracy and consistency of MAT, making it a more reliable alternative to traditional animal testing methods. The ability to simulate the human immune response with these cell lines has

improved the sensitivity of MAT, allowing for better detection of pyrogens, including both endotoxins and non-endotoxins.

Another innovation is the automation of MAT processes, which has streamlined testing workflows and reduced the time required to obtain results. Automated systems for preparing and analyzing MAT samples have increased throughput, making it more feasible for large-scale pharmaceutical and biotechnology companies to incorporate MAT into their quality control processes. Minerva Biolabs' next-generation MAT system, the NAT-MAT, represents a significant advancement in pyrogen testing. By utilizing digital PCR to measure the gene expression of IL-1 β and TNF- α , the NAT-MAT provides highly sensitive and reliable results for detecting both endotoxin and non-endotoxin pyrogens. This system is optimized for fast testing, making it suitable for in-process control and final release testing of medicinal products, in line with Ph. Eur. 2.6.30 standards.

The key innovation in the NAT-MAT[®] lies in the parallel measurement of two cytokines alongside a housekeeping gene, which improves the accuracy of results. The housekeeping gene serves a dual purpose: it acts as a quality control for both the extraction process and cell density, ensuring the assay functions reliably across different cell densities. Additionally, the automated analysis through Minerva Biolabs' specialized software streamlines the process, ensuring compliance with regulatory requirements while enhancing testing efficiency.

This technology provides a significant improvement over traditional pyrogen testing methods by offering a more comprehensive and precise approach to ensuring the safety of pharmaceutical and biotechnological products. For example, companies like Lonza Group and Charles River Laboratories have integrated advanced cell culture technologies and automated systems into their MAT offerings, improving efficiency and scalability. Furthermore, advancements in high-throughput screening technologies have enabled faster and more cost-effective pyrogen testing, allowing MAT to be used in drug development and vaccine production more widely. These technological innovations continue to enhance MAT's adoption, making it an essential tool for ensuring the safety and efficacy of pharmaceutical and biotechnological products.

Monocyte Activation Test Market Report Highlights

Based on product, MAT Kits segment accounted for largest revenue share of 63.7% in 2024. The MAT Kits segment is experiencing growth due

the increasing demand for reliable, human-relevant pyrogen testing methods. A key driving factor is the growing regulatory pressure to replace animal testing with in vitro alternatives. MAT kits offer a precise and ethical solution by using human immune cells to detect endotoxins and non-endotoxin pyrogens, ensuring the safety of pharmaceutical products. Additionally, the rising prevalence of biologics, vaccines, and complex drug formulations is driving the demand for MAT kits, as these products require stringent safety testing before reaching the market. The convenience and accuracy of MAT kits further boost their adoption.

Based on source, PBMC dominated the market and accounted for the largest share of 62.7% in 2024, due to the increasing demand for human-based, ethical alternatives to animal testing. PBMCs, which include monocytes, are critical for detecting pyrogens as they closely mimic the human immune response. This human-relevant testing method is gaining favor due to its ability to provide more accurate and reproducible results compared to traditional animal models. Additionally, the rise in biologic drug development, vaccines, and regulatory pressures

to replace animal testing with in vitro methods further drives the adoption of PBMC-based MAT testing.

Based on application, drug development dominated the market and accounted for the largest share of 40.6% in 2024, due to increasing demand for accurate and reliable pyrogen testing methods. As the pharmaceutical industry develops more complex biologics and vaccines, ensuring product safety through rigorous testing is crucial. MAT provides an in vitro, human-relevant approach to detect endotoxins and non-endotoxin pyrogens, replacing traditional animal testing methods. Regulatory bodies like the FDA and EMA endorse MAT as a valid alternative, further promoting its adoption in drug development. The growing focus on patient safety, regulatory compliance, and the need for faster testing methods are key driving factors.

Based on end use, pharmaceutical industry segment is dominated the end use segments with the largest market share of 56.3% in 2024. The market growth is fueled by factors such as increasing need for reliable pyrogen testing in drug development and manufacturing. As the industry focuses on producing biologics, vaccines, and other complex therapeutic products, ensuring their safety is paramount. MAT, with its ability to detect endotoxins and non-endotoxin pyrogens using human immune cells, provides an accurate and ethical alternative to traditional animal testing. Regulatory agencies like the FDA and EMA support MAT's use, driving its adoption. The growing demand for safer, faster, and more efficient testing methods in pharmaceutical production is a key factor fueling MAT's market growth.

North America dominated the global market, primary driver is the region's stringent regulatory environment, with agencies like the FDA and Health Canada increasingly endorsing MAT as a reliable and ethical alternative to traditional animal testing. The demand

for MAT is also fueled by the growing biologics and vaccine sectors, where ensuring product safety is crucial. Additionally, the rising focus on patient safety, advancements in biotechnology, and the need for more efficient and human-relevant pyrogen testing methods are contributing to the widespread adoption of MAT in North America.

Asia Pacific region is expected to witness fastest growth with a CAGR of 17.3% over the forecast period from 2025 to 2030, rapid advancements in the pharmaceutical and biotechnology sectors. The growing demand for biologics, vaccines, and complex therapeutics in countries like China, Japan, and India is a major factor. Regulatory authorities in these countries are increasingly adopting MAT as a preferred alternative to traditional animal testing, aligning with global ethical standards. Additionally, the rising focus on patient safety and the need for more efficient, human-relevant testing methods are driving MAT adoption. The region's expanding healthcare infrastructure further supports MAT's growing market presence.

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Product
 - 1.2.2. Source
 - 1.2.3. Application
 - 1.2.4. End-use
 - 1.2.5. Regional scope
 - 1.2.6. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
 - 1.4.1. Purchased database
 - 1.4.2. GVR's internal database
 - 1.4.3. Secondary sources
 - 1.4.4. Primary research
 - 1.4.5. Details of primary research
 - 1.4.5.1. Data for primary interviews in North America
 - 1.4.5.2. Data for primary interviews in Europe
 - 1.4.5.3. Data for primary interviews in Asia Pacific
 - 1.4.5.4. Data for primary interviews in Latin America
 - 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
 - 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
 - 1.7.1. Commodity flow analysis (Model 1)
 - 1.7.2. Approach 1: Commodity flow approach
 - 1.7.3. Volume price analysis (Model 2)
 - 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook

- 2.2. Segment Outlook
 - 2.2.1. Product and source outlook
 - 2.2.2. Application and end use outlook
 - 2.2.3. Regional outlook
- 2.3. Competitive Insights

CHAPTER 3. MONOCYTE ACTIVATION TEST (MAT) MARKET VARIABLES, TRENDS & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent market outlook
 - 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
 - 3.2.1. Market driver analysis
 - 3.2.1.1. Increasing demand for safer and more accurate alternatives to LAL (Limulus Amebocyte Lysate) test
 - 3.2.1.2. Rising regulatory requirements for medical devices and pharmaceuticals
 - 3.2.1.3. Growing adoption of in vitro testing methods
 - 3.2.2. Market restraint analysis
 - 3.2.2.1. High initial setup costs
 - 3.2.2.2. Limited standardization and adoption across all regulatory frameworks
- 3.3. Monocyte activation test (MAT) Market Analysis Tools
 - 3.3.1. Industry Analysis – Porter's
 - 3.3.1.1. Supplier power
 - 3.3.1.2. Buyer power
 - 3.3.1.3. Substitution threat
 - 3.3.1.4. Threat of new entrant
 - 3.3.1.5. Competitive rivalry
 - 3.3.2. PESTEL Analysis
 - 3.3.2.1. Political landscape
 - 3.3.2.2. Technological landscape
 - 3.3.2.3. Economic landscape
 - 3.3.3. Pricing Analysis

CHAPTER 4. MONOCYTE ACTIVATION TEST (MAT) MARKET: PRODUCT ESTIMATES & TREND ANALYSIS

- 4.1. Global Monocyte activation test (MAT) Market: Product Dashboard
- 4.2. Global Monocyte activation test (MAT) Market: Product Movement Analysis

4.3. Global Monocyte activation test (MAT) Market by Product, Revenue

4.4. MAT Kits

4.4.1. MAT kits market estimates and forecasts 2018 to 2030 (USD Million)

4.5. Reagents

4.5.1. Reagents market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 5. MONOCYTE ACTIVATION TEST (MAT) MARKET: APPLICATION ESTIMATES & TREND ANALYSIS

5.1. Global Monocyte activation test (MAT) Market: Application Dashboard

5.2. Global Monocyte activation test (MAT) Market: Application Movement Analysis

5.3. Global Monocyte activation test (MAT) Market by Application , Revenue

5.4. Drug Development

5.4.1. Drug Development market estimates and forecasts 2018 to 2030 (USD Million)

5.5. Vaccine Development

5.5.1. Vaccine Development market estimates and forecasts 2018 to 2030 (USD Million)

5.6. Medical Device Testing

5.6.1. Medical Device Testing market estimates and forecasts 2018 to 2030 (USD Million)

5.7. Others

5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 6. MONOCYTE ACTIVATION TEST (MAT) MARKET: SOURCE ESTIMATES & TREND ANALYSIS

6.1. Global Monocyte activation test (MAT) Market: Source Dashboard

6.2. Global Monocyte activation test (MAT) Market: Source Movement Analysis

6.3. Global Monocyte activation test (MAT) Market by Source, Revenue

6.4. PBMC Based

6.4.1. PBMC Based market estimates and forecasts 2018 to 2030 (USD Million)

6.5. Cell Line Based

6.5.1. Cell Line Based market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 7. MONOCYTE ACTIVATION TEST (MAT) MARKET: END USE ESTIMATES & TREND ANALYSIS

7.1. Global Monocyte activation test (MAT) Market: End use Dashboard

7.2. Global Monocyte activation test (MAT) Market: End use Movement Analysis

7.3. Global Monocyte activation test (MAT) Market by End use, Revenue

7.4. Pharmaceutical Industry

7.4.1. Pharmaceutical Industry market estimates and forecasts 2018 to 2030 (USD Million)

7.5. Biotechnology Industry

7.5.1. Biotechnology Industry market estimates and forecasts 2018 to 2030 (USD Million)

7.6. Medical Device Industry

7.6.1. Medical Device Industry Analysis market estimates and forecasts 2018 to 2030 (USD Million)

7.7. Others

7.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 8. MONOCYTE ACTIVATION TEST (MAT) MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY PRODUCT, SOURCE, APPLICATION AND METHODOLOGY

8.1. Regional Dashboard

8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:

8.3. North America

8.3.1. U.S.

8.3.1.1. Key country dynamics

8.3.1.2. Regulatory framework/ reimbursement structure

8.3.1.3. Competitive scenario

8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)

8.3.2. Canada

8.3.2.1. Key country dynamics

8.3.2.2. Regulatory framework/ reimbursement structure

8.3.2.3. Competitive scenario

8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)

8.3.3. Mexico

8.3.3.1. Key country dynamics

8.3.3.2. Regulatory framework/ reimbursement structure

8.3.3.3. Competitive scenario

8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)

8.4. Europe

8.4.1. UK

8.4.1.1. Key country dynamics

8.4.1.2. Regulatory framework/ reimbursement structure

- 8.4.1.3. Competitive scenario
- 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.2. Germany
 - 8.4.2.1. Key country dynamics
 - 8.4.2.2. Regulatory framework/ reimbursement structure
 - 8.4.2.3. Competitive scenario
 - 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.3. France
 - 8.4.3.1. Key country dynamics
 - 8.4.3.2. Regulatory framework/ reimbursement structure
 - 8.4.3.3. Competitive scenario
 - 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.4. Italy
 - 8.4.4.1. Key country dynamics
 - 8.4.4.2. Regulatory framework/ reimbursement structure
 - 8.4.4.3. Competitive scenario
 - 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.5. Spain
 - 8.4.5.1. Key country dynamics
 - 8.4.5.2. Regulatory framework/ reimbursement structure
 - 8.4.5.3. Competitive scenario
 - 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.6. Norway
 - 8.4.6.1. Key country dynamics
 - 8.4.6.2. Regulatory framework/ reimbursement structure
 - 8.4.6.3. Competitive scenario
 - 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.7. Sweden
 - 8.4.7.1. Key country dynamics
 - 8.4.7.2. Regulatory framework/ reimbursement structure
 - 8.4.7.3. Competitive scenario
 - 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.8. Denmark
 - 8.4.8.1. Key country dynamics
 - 8.4.8.2. Regulatory framework/ reimbursement structure
 - 8.4.8.3. Competitive scenario
 - 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5. Asia Pacific
 - 8.5.1. Japan

- 8.5.1.1. Key country dynamics
- 8.5.1.2. Regulatory framework/ reimbursement structure
- 8.5.1.3. Competitive scenario
- 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.2. China
 - 8.5.2.1. Key country dynamics
 - 8.5.2.2. Regulatory framework/ reimbursement structure
 - 8.5.2.3. Competitive scenario
 - 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.3. India
 - 8.5.3.1. Key country dynamics
 - 8.5.3.2. Regulatory framework/ reimbursement structure
 - 8.5.3.3. Competitive scenario
 - 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.4. Australia
 - 8.5.4.1. Key country dynamics
 - 8.5.4.2. Regulatory framework/ reimbursement structure
 - 8.5.4.3. Competitive scenario
 - 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.5. South Korea
 - 8.5.5.1. Key country dynamics
 - 8.5.5.2. Regulatory framework/ reimbursement structure
 - 8.5.5.3. Competitive scenario
 - 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.6. Thailand
 - 8.5.6.1. Key country dynamics
 - 8.5.6.2. Regulatory framework/ reimbursement structure
 - 8.5.6.3. Competitive scenario
 - 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6. Latin America
 - 8.6.1. Brazil
 - 8.6.1.1. Key country dynamics
 - 8.6.1.2. Regulatory framework/ reimbursement structure
 - 8.6.1.3. Competitive scenario
 - 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
 - 8.6.2. Argentina
 - 8.6.2.1. Key country dynamics
 - 8.6.2.2. Regulatory framework/ reimbursement structure
 - 8.6.2.3. Competitive scenario

8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)

8.7. MEA

8.7.1. South Africa

8.7.1.1. Key country dynamics

8.7.1.2. Regulatory framework/ reimbursement structure

8.7.1.3. Competitive scenario

8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)

8.7.2. Saudi Arabia

8.7.2.1. Key country dynamics

8.7.2.2. Regulatory framework/ reimbursement structure

8.7.2.3. Competitive scenario

8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)

8.7.3. UAE

8.7.3.1. Key country dynamics

8.7.3.2. Regulatory framework/ reimbursement structure

8.7.3.3. Competitive scenario

8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)

8.7.4. Kuwait

8.7.4.1. Key country dynamics

8.7.4.2. Regulatory framework/ reimbursement structure

8.7.4.3. Competitive scenario

8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 9. COMPETITIVE LANDSCAPE

9.1. Recent Developments & Impact Analysis, By Key Market Participants

9.2. Company/Competition Categorization

9.3. Vendor Landscape

9.3.1. List of key distributors and channel partners

9.3.2. Key customers

9.3.3. Key company market share analysis, 2024

9.3.4. Lonza Group

9.3.4.1. Company overview

9.3.4.2. Financial performance

9.3.4.3. Product benchmarking

9.3.4.4. Strategic initiatives

9.3.5. Charles River Laboratories

9.3.5.1. Company overview

9.3.5.2. Financial performance

- 9.3.5.3. Product benchmarking
- 9.3.5.4. Strategic initiatives
- 9.3.6. Bio-Rad Laboratories
 - 9.3.6.1. Company overview
 - 9.3.6.2. Financial performance
 - 9.3.6.3. Product benchmarking
 - 9.3.6.4. Strategic initiatives
- 9.3.7. Seikagaku Corporation
 - 9.3.7.1. Company overview
 - 9.3.7.2. Financial performance
 - 9.3.7.3. Product benchmarking
 - 9.3.7.4. Strategic initiatives
- 9.3.8. Hyglos GmbH
 - 9.3.8.1. Company overview
 - 9.3.8.2. Financial performance
 - 9.3.8.3. Product benchmarking
 - 9.3.8.4. Strategic initiatives
- 9.3.9. Hyglos GmbH
 - 9.3.9.1. Company overview
 - 9.3.9.2. Financial performance
 - 9.3.9.3. Product benchmarking
 - 9.3.9.4. Strategic initiatives
- 9.3.10. Thermo Fisher Scientific
 - 9.3.10.1. Company overview
 - 9.3.10.2. Financial performance
 - 9.3.10.3. Product benchmarking
 - 9.3.10.4. Strategic initiatives
- 9.3.11. MAT BioTech
 - 9.3.11.1. Company overview
 - 9.3.11.2. Financial performance
 - 9.3.11.3. Product benchmarking
 - 9.3.11.4. Strategic initiatives
- 9.3.12. Eurofins Scientific
 - 9.3.12.1. Company overview
 - 9.3.12.2. Financial performance
 - 9.3.12.3. Product benchmarking
 - 9.3.12.4. Strategic initiatives

I would like to order

Product name: Monocyte Activation Test Market Size, Share & Trends Analysis Report By Product (MAT Kits, Reagents), By Source (PBMC Based, Cell Line Based), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/M03ABED99E91EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M03ABED99E91EN.html>